TrialThe Lancet. Infectious diseases2021

Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.

James S McCarthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.